Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Curadev India
Bayer Back In M&A Mode To Boost Pipeline
The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.
Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease
Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.
Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.